Nilofabicin

Nilofabicin
Clinical data
Other names	CG-400549
Identifiers
	IUPAC name 1-[(3-amino-2-methylphenyl)methyl]-4-(2-thiophen-2-ylethoxy)pyridin-2-one;
CAS Number	934628-27-0 ;
PubChem CID	11844916 ;
IUPHAR/BPS	10984 ;
DrugBank	DB12347 ;
ChemSpider	10019391 ;
UNII	4X6T64D64X ;
ChEMBL	ChEMBL488937 ;
CompTox Dashboard (EPA)	DTXSID00239434 ;
Chemical and physical data
Formula	C19H20N2O2S
Molar mass	340.44 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES CC1=C(C=CC=C1N)CN2C=CC(=CC2=O)OCCC3=CC=CS3;
	InChI InChI=1S/C19H20N2O2S/c1-14-15(4-2-6-18(14)20)13-21-9-7-16(12-19(21)22)23-10-8-17-5-3-11-24-17/h2-7,9,11-12H,8,10,13,20H2,1H3; Key:YCLREGRRHGLOAK-UHFFFAOYSA-N;

Last updated June 15, 2025

Nilofabicin (CG-400549) is an experimental antibiotic medication related to afabicin, which acts as an inhibitor of the bacterial enzyme enoyl-acyl carrier protein reductase (FabI). It is being researched as a potential treatment for infections by drug-resistant strains of bacteria such as Staphylococcus aureus , Klebsiella pneumoniae and Pseudomonas aeruginosa .^[1]^[2]^[3]^[4]^[5]

References

↑ Park HS, Yoon YM, Jung SJ, Kim CM, Kim JM, Kwak JH (September 2007). "Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor". The Journal of Antimicrobial Chemotherapy. 60 (3): 568–74. doi:10.1093/jac/dkm236. PMID 17606482.
↑ Hernández-Vázquez E, Ramírez-Trinidad Á, Tovar-Román CE, Rivera Chávez JA, Huerta-Salazar E (November 2024). "N-acyl-4-arylaminopiperidines: Design and synthesis of a potential antimicrobial scaffold". Bioorganic & Medicinal Chemistry Letters. 112: 129936. doi: 10.1016/j.bmcl.2024.129936 . PMID 39214507.
↑ Douglas EJ, Wulandari SW, Lovell SD, Laabei M (July 2023). "Novel antimicrobial strategies to treat multi-drug resistant Staphylococcus aureus infections". Microbial Biotechnology. 16 (7): 1456–1474. doi:10.1111/1751-7915.14268. PMC 10281381 . PMID 37178319.
↑ Theuretzbacher U (October 2023). "Evaluating the innovative potential of the global antibacterial pipeline". Clinical Microbiology and Infection. doi:10.1016/j.cmi.2023.09.024. PMID 37805036.
↑ Süssmuth RD, Kulike-Koczula M, Gao P, Kosol S (November 2024). "Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research". Angewandte Chemie: e202414325. doi: 10.1002/anie.202414325 . PMC 11878372 . PMID 39611429.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[pmid17606482-1] Park HS, Yoon YM, Jung SJ, Kim CM, Kim JM, Kwak JH (September 2007). "Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor". The Journal of Antimicrobial Chemotherapy. 60 (3): 568–74. doi:10.1093/jac/dkm236. PMID 17606482.

[2] Hernández-Vázquez E, Ramírez-Trinidad Á, Tovar-Román CE, Rivera Chávez JA, Huerta-Salazar E (November 2024). "N-acyl-4-arylaminopiperidines: Design and synthesis of a potential antimicrobial scaffold". Bioorganic & Medicinal Chemistry Letters. 112: 129936. doi: 10.1016/j.bmcl.2024.129936 . PMID 39214507.

[3] Douglas EJ, Wulandari SW, Lovell SD, Laabei M (July 2023). "Novel antimicrobial strategies to treat multi-drug resistant Staphylococcus aureus infections". Microbial Biotechnology. 16 (7): 1456–1474. doi:10.1111/1751-7915.14268. PMC 10281381 . PMID 37178319.

[4] Theuretzbacher U (October 2023). "Evaluating the innovative potential of the global antibacterial pipeline". Clinical Microbiology and Infection. doi:10.1016/j.cmi.2023.09.024. PMID 37805036.

[5] Süssmuth RD, Kulike-Koczula M, Gao P, Kosol S (November 2024). "Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research". Angewandte Chemie: e202414325. doi: 10.1002/anie.202414325 . PMC 11878372 . PMID 39611429.

[1]

[2]

[3]

[4]

[5]